Wedbush Reiterates Outperform on Tyra Biosciences, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Tyra Biosciences (NASDAQ:TYRA) and maintained a $28 price target.

July 03, 2024 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Tyra Biosciences and maintained a $28 price target, indicating strong confidence in the company's future performance.
The reiteration of an Outperform rating and a maintained price target of $28 by a reputable analyst suggests positive sentiment and confidence in Tyra Biosciences' future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100